Efficacy of bevacizumab maintenance therapy in advanced ovarian cancer Article Swipe
Qing Kai Han
,
Aiqin He
,
Haibo Xu
,
Can Zhang
,
Yunfen Qiu
,
Yong Li
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.29063/ajrh2025/v29i7.10
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.29063/ajrh2025/v29i7.10
This study aimed to evaluate the efficacy of bevacizumab maintenance therapy in advanced ovarian cancer and its impact on the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/vascular endothelial growth factor A (VEGFA) pathway. A total of 126 patients were enrolled, divided into two groups: control (n=62) and study (n=64). The control group received neoadjuvant chemotherapy, tumor debulking surgery, and postoperative adjuvant chemotherapy. The research group received postoperative bevacizumab maintenance therapy in addition to standard treatment. Results showed that the research group had significantly improved disease control rates (43.75% vs. 24.19%, P=0.0206), objective response rates (76.56% vs. 48.39%, P=0.0011), overall survival (30.45±7.69 months vs. 22.92±7.26 months, P<0.0001) and progression-free survival (16.08±2.46 months vs. 12.08±2.25 months) compared to controls. Bevacizumab also led to lower levels of Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3) and vascular endothelial growth factor A (VEGFA) expression. This therapy demonstrated safety and efficacy, significantly prolonging progression-free survival and overall survival.
Related Topics
Concepts
Bevacizumab
Medicine
Vascular endothelial growth factor
Internal medicine
Janus kinase
Maintenance therapy
Oncology
STAT protein
STAT3
Ovarian cancer
Debulking
Vascular endothelial growth factor A
Chemotherapy
Surgery
Cancer
Apoptosis
Cytokine
VEGF receptors
Chemistry
Biochemistry
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.29063/ajrh2025/v29i7.10
- OA Status
- diamond
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4412678318
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4412678318Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.29063/ajrh2025/v29i7.10Digital Object Identifier
- Title
-
Efficacy of bevacizumab maintenance therapy in advanced ovarian cancerWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-07-27Full publication date if available
- Authors
-
Qing Kai Han, Aiqin He, Haibo Xu, Can Zhang, Yunfen Qiu, Yong LiList of authors in order
- Landing page
-
https://doi.org/10.29063/ajrh2025/v29i7.10Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.29063/ajrh2025/v29i7.10Direct OA link when available
- Concepts
-
Bevacizumab, Medicine, Vascular endothelial growth factor, Internal medicine, Janus kinase, Maintenance therapy, Oncology, STAT protein, STAT3, Ovarian cancer, Debulking, Vascular endothelial growth factor A, Chemotherapy, Surgery, Cancer, Apoptosis, Cytokine, VEGF receptors, Chemistry, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4412678318 |
|---|---|
| doi | https://doi.org/10.29063/ajrh2025/v29i7.10 |
| ids.doi | https://doi.org/10.29063/ajrh2025/v29i7.10 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40728281 |
| ids.openalex | https://openalex.org/W4412678318 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D005260 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Female |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D000068258 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Bevacizumab |
| mesh[3].qualifier_ui | Q000008 |
| mesh[3].descriptor_ui | D000068258 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | administration & dosage |
| mesh[3].descriptor_name | Bevacizumab |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D010051 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Ovarian Neoplasms |
| mesh[5].qualifier_ui | Q000401 |
| mesh[5].descriptor_ui | D010051 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | mortality |
| mesh[5].descriptor_name | Ovarian Neoplasms |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D008875 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Middle Aged |
| mesh[7].qualifier_ui | Q000378 |
| mesh[7].descriptor_ui | D042461 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | metabolism |
| mesh[7].descriptor_name | Vascular Endothelial Growth Factor A |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D000328 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Adult |
| mesh[9].qualifier_ui | Q000378 |
| mesh[9].descriptor_ui | D053614 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | metabolism |
| mesh[9].descriptor_name | Janus Kinase 2 |
| mesh[10].qualifier_ui | Q000378 |
| mesh[10].descriptor_ui | D050796 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | metabolism |
| mesh[10].descriptor_name | STAT3 Transcription Factor |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000368 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Aged |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D016896 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Treatment Outcome |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D000074322 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[14].qualifier_ui | Q000008 |
| mesh[14].descriptor_ui | D000074322 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | administration & dosage |
| mesh[14].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D060046 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Maintenance Chemotherapy |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D017024 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Chemotherapy, Adjuvant |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000077982 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Progression-Free Survival |
| type | article |
| title | Efficacy of bevacizumab maintenance therapy in advanced ovarian cancer |
| biblio.issue | 7 |
| biblio.volume | 29 |
| biblio.last_page | 116 |
| biblio.first_page | 107 |
| topics[0].id | https://openalex.org/T10550 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9994000196456909 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2743 |
| topics[0].subfield.display_name | Reproductive Medicine |
| topics[0].display_name | Ovarian cancer diagnosis and treatment |
| topics[1].id | https://openalex.org/T13185 |
| topics[1].field.id | https://openalex.org/fields/25 |
| topics[1].field.display_name | Materials Science |
| topics[1].score | 0.9706000089645386 |
| topics[1].domain.id | https://openalex.org/domains/3 |
| topics[1].domain.display_name | Physical Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2502 |
| topics[1].subfield.display_name | Biomaterials |
| topics[1].display_name | Phytochemistry and Bioactive Compounds |
| topics[2].id | https://openalex.org/T13779 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9634000062942505 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Cancer Mechanisms and Therapy |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777802072 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8814206123352051 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[0].display_name | Bevacizumab |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.858026385307312 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2777025900 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6328338384628296 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q29725 |
| concepts[2].display_name | Vascular endothelial growth factor |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5611459612846375 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C112392421 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5540333986282349 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q903451 |
| concepts[4].display_name | Janus kinase |
| concepts[5].id | https://openalex.org/C2778283404 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5524260401725769 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q6736822 |
| concepts[5].display_name | Maintenance therapy |
| concepts[6].id | https://openalex.org/C143998085 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5405726432800293 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[6].display_name | Oncology |
| concepts[7].id | https://openalex.org/C171958077 |
| concepts[7].level | 4 |
| concepts[7].score | 0.5395914316177368 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q419333 |
| concepts[7].display_name | STAT protein |
| concepts[8].id | https://openalex.org/C2778923194 |
| concepts[8].level | 3 |
| concepts[8].score | 0.524286687374115 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q14912019 |
| concepts[8].display_name | STAT3 |
| concepts[9].id | https://openalex.org/C2780427987 |
| concepts[9].level | 3 |
| concepts[9].score | 0.48163455724716187 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q172341 |
| concepts[9].display_name | Ovarian cancer |
| concepts[10].id | https://openalex.org/C2781100745 |
| concepts[10].level | 4 |
| concepts[10].score | 0.43993157148361206 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1977435 |
| concepts[10].display_name | Debulking |
| concepts[11].id | https://openalex.org/C146285616 |
| concepts[11].level | 4 |
| concepts[11].score | 0.43229299783706665 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7916455 |
| concepts[11].display_name | Vascular endothelial growth factor A |
| concepts[12].id | https://openalex.org/C2776694085 |
| concepts[12].level | 2 |
| concepts[12].score | 0.4179399609565735 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[12].display_name | Chemotherapy |
| concepts[13].id | https://openalex.org/C141071460 |
| concepts[13].level | 1 |
| concepts[13].score | 0.4057964086532593 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[13].display_name | Surgery |
| concepts[14].id | https://openalex.org/C121608353 |
| concepts[14].level | 2 |
| concepts[14].score | 0.2950178384780884 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[14].display_name | Cancer |
| concepts[15].id | https://openalex.org/C190283241 |
| concepts[15].level | 2 |
| concepts[15].score | 0.15339258313179016 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q14599311 |
| concepts[15].display_name | Apoptosis |
| concepts[16].id | https://openalex.org/C2778690821 |
| concepts[16].level | 2 |
| concepts[16].score | 0.1255592703819275 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q212354 |
| concepts[16].display_name | Cytokine |
| concepts[17].id | https://openalex.org/C167734588 |
| concepts[17].level | 2 |
| concepts[17].score | 0.11298230290412903 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q4356503 |
| concepts[17].display_name | VEGF receptors |
| concepts[18].id | https://openalex.org/C185592680 |
| concepts[18].level | 0 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[18].display_name | Chemistry |
| concepts[19].id | https://openalex.org/C55493867 |
| concepts[19].level | 1 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[19].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/bevacizumab |
| keywords[0].score | 0.8814206123352051 |
| keywords[0].display_name | Bevacizumab |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.858026385307312 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/vascular-endothelial-growth-factor |
| keywords[2].score | 0.6328338384628296 |
| keywords[2].display_name | Vascular endothelial growth factor |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.5611459612846375 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/janus-kinase |
| keywords[4].score | 0.5540333986282349 |
| keywords[4].display_name | Janus kinase |
| keywords[5].id | https://openalex.org/keywords/maintenance-therapy |
| keywords[5].score | 0.5524260401725769 |
| keywords[5].display_name | Maintenance therapy |
| keywords[6].id | https://openalex.org/keywords/oncology |
| keywords[6].score | 0.5405726432800293 |
| keywords[6].display_name | Oncology |
| keywords[7].id | https://openalex.org/keywords/stat-protein |
| keywords[7].score | 0.5395914316177368 |
| keywords[7].display_name | STAT protein |
| keywords[8].id | https://openalex.org/keywords/stat3 |
| keywords[8].score | 0.524286687374115 |
| keywords[8].display_name | STAT3 |
| keywords[9].id | https://openalex.org/keywords/ovarian-cancer |
| keywords[9].score | 0.48163455724716187 |
| keywords[9].display_name | Ovarian cancer |
| keywords[10].id | https://openalex.org/keywords/debulking |
| keywords[10].score | 0.43993157148361206 |
| keywords[10].display_name | Debulking |
| keywords[11].id | https://openalex.org/keywords/vascular-endothelial-growth-factor-a |
| keywords[11].score | 0.43229299783706665 |
| keywords[11].display_name | Vascular endothelial growth factor A |
| keywords[12].id | https://openalex.org/keywords/chemotherapy |
| keywords[12].score | 0.4179399609565735 |
| keywords[12].display_name | Chemotherapy |
| keywords[13].id | https://openalex.org/keywords/surgery |
| keywords[13].score | 0.4057964086532593 |
| keywords[13].display_name | Surgery |
| keywords[14].id | https://openalex.org/keywords/cancer |
| keywords[14].score | 0.2950178384780884 |
| keywords[14].display_name | Cancer |
| keywords[15].id | https://openalex.org/keywords/apoptosis |
| keywords[15].score | 0.15339258313179016 |
| keywords[15].display_name | Apoptosis |
| keywords[16].id | https://openalex.org/keywords/cytokine |
| keywords[16].score | 0.1255592703819275 |
| keywords[16].display_name | Cytokine |
| keywords[17].id | https://openalex.org/keywords/vegf-receptors |
| keywords[17].score | 0.11298230290412903 |
| keywords[17].display_name | VEGF receptors |
| language | en |
| locations[0].id | doi:10.29063/ajrh2025/v29i7.10 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S22933603 |
| locations[0].source.issn | 1118-4841 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1118-4841 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | African Journal of Reproductive Health |
| locations[0].source.host_organization | https://openalex.org/P4310321518 |
| locations[0].source.host_organization_name | African Journals OnLine |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310321518 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | African Journal of Reproductive Health |
| locations[0].landing_page_url | https://doi.org/10.29063/ajrh2025/v29i7.10 |
| locations[1].id | pmid:40728281 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | African journal of reproductive health |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40728281 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5109187556 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Qing Kai Han |
| authorships[0].countries | CN |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210105390 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[0].institutions[0].id | https://openalex.org/I4210105390 |
| authorships[0].institutions[0].ror | https://ror.org/01egmr022 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210105390 |
| authorships[0].institutions[0].country_code | CN |
| authorships[0].institutions[0].display_name | Nantong Tumor Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Qing Han |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[1].author.id | https://openalex.org/A5079702358 |
| authorships[1].author.orcid | https://orcid.org/0009-0002-8955-1441 |
| authorships[1].author.display_name | Aiqin He |
| authorships[1].countries | CN |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210105390 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[1].institutions[0].id | https://openalex.org/I4210105390 |
| authorships[1].institutions[0].ror | https://ror.org/01egmr022 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210105390 |
| authorships[1].institutions[0].country_code | CN |
| authorships[1].institutions[0].display_name | Nantong Tumor Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Aiqin He |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[2].author.id | https://openalex.org/A5084980098 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-3713-3144 |
| authorships[2].author.display_name | Haibo Xu |
| authorships[2].countries | CN |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210105390 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[2].institutions[0].id | https://openalex.org/I4210105390 |
| authorships[2].institutions[0].ror | https://ror.org/01egmr022 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210105390 |
| authorships[2].institutions[0].country_code | CN |
| authorships[2].institutions[0].display_name | Nantong Tumor Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Haibo Xu |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[3].author.id | https://openalex.org/A5100440848 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3529-5438 |
| authorships[3].author.display_name | Can Zhang |
| authorships[3].countries | CN |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210105390 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[3].institutions[0].id | https://openalex.org/I4210105390 |
| authorships[3].institutions[0].ror | https://ror.org/01egmr022 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210105390 |
| authorships[3].institutions[0].country_code | CN |
| authorships[3].institutions[0].display_name | Nantong Tumor Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Can Zhang |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[4].author.id | https://openalex.org/A5059164515 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Yunfen Qiu |
| authorships[4].countries | CN |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210105390 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[4].institutions[0].id | https://openalex.org/I4210105390 |
| authorships[4].institutions[0].ror | https://ror.org/01egmr022 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210105390 |
| authorships[4].institutions[0].country_code | CN |
| authorships[4].institutions[0].display_name | Nantong Tumor Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Yunfen Qiu |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[5].author.id | https://openalex.org/A5100355454 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-1486-841X |
| authorships[5].author.display_name | Yong Li |
| authorships[5].countries | CN |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210105390 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| authorships[5].institutions[0].id | https://openalex.org/I4210105390 |
| authorships[5].institutions[0].ror | https://ror.org/01egmr022 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210105390 |
| authorships[5].institutions[0].country_code | CN |
| authorships[5].institutions[0].display_name | Nantong Tumor Hospital |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Yong Li |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Gynecologic Oncology, Nantong Tumor Hospital, Nantong 226300, Jiangsu province, China. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.29063/ajrh2025/v29i7.10 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Efficacy of bevacizumab maintenance therapy in advanced ovarian cancer |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10550 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9994000196456909 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2743 |
| primary_topic.subfield.display_name | Reproductive Medicine |
| primary_topic.display_name | Ovarian cancer diagnosis and treatment |
| related_works | https://openalex.org/W4404534319, https://openalex.org/W4283734508, https://openalex.org/W4200511349, https://openalex.org/W2578499730, https://openalex.org/W4244640182, https://openalex.org/W3032767292, https://openalex.org/W2166643395, https://openalex.org/W4229439711, https://openalex.org/W4396768048, https://openalex.org/W4407240488 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.29063/ajrh2025/v29i7.10 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S22933603 |
| best_oa_location.source.issn | 1118-4841 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1118-4841 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | African Journal of Reproductive Health |
| best_oa_location.source.host_organization | https://openalex.org/P4310321518 |
| best_oa_location.source.host_organization_name | African Journals OnLine |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310321518 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | African Journal of Reproductive Health |
| best_oa_location.landing_page_url | https://doi.org/10.29063/ajrh2025/v29i7.10 |
| primary_location.id | doi:10.29063/ajrh2025/v29i7.10 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S22933603 |
| primary_location.source.issn | 1118-4841 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1118-4841 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | African Journal of Reproductive Health |
| primary_location.source.host_organization | https://openalex.org/P4310321518 |
| primary_location.source.host_organization_name | African Journals OnLine |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310321518 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | African Journal of Reproductive Health |
| primary_location.landing_page_url | https://doi.org/10.29063/ajrh2025/v29i7.10 |
| publication_date | 2025-07-27 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 22, 130 |
| abstract_inverted_index.3 | 29, 138 |
| abstract_inverted_index.A | 34, 37, 145 |
| abstract_inverted_index.in | 11, 74 |
| abstract_inverted_index.of | 7, 27, 39, 127, 136 |
| abstract_inverted_index.on | 18 |
| abstract_inverted_index.to | 3, 76, 119, 124 |
| abstract_inverted_index.126 | 40 |
| abstract_inverted_index.The | 53, 66 |
| abstract_inverted_index.and | 15, 25, 50, 62, 110, 134, 140, 152, 158 |
| abstract_inverted_index.had | 85 |
| abstract_inverted_index.its | 16 |
| abstract_inverted_index.led | 123 |
| abstract_inverted_index.the | 5, 19, 82 |
| abstract_inverted_index.two | 46 |
| abstract_inverted_index.vs. | 92, 99, 106, 115 |
| abstract_inverted_index.This | 0, 148 |
| abstract_inverted_index.also | 122 |
| abstract_inverted_index.into | 45 |
| abstract_inverted_index.that | 81 |
| abstract_inverted_index.were | 42 |
| abstract_inverted_index.Janus | 20, 128 |
| abstract_inverted_index.aimed | 2 |
| abstract_inverted_index.group | 55, 68, 84 |
| abstract_inverted_index.lower | 125 |
| abstract_inverted_index.rates | 90, 97 |
| abstract_inverted_index.study | 1, 51 |
| abstract_inverted_index.total | 38 |
| abstract_inverted_index.tumor | 59 |
| abstract_inverted_index.(n=62) | 49 |
| abstract_inverted_index.cancer | 14 |
| abstract_inverted_index.factor | 33, 144 |
| abstract_inverted_index.growth | 32, 143 |
| abstract_inverted_index.impact | 17 |
| abstract_inverted_index.kinase | 21, 129 |
| abstract_inverted_index.levels | 126 |
| abstract_inverted_index.months | 105, 114 |
| abstract_inverted_index.safety | 151 |
| abstract_inverted_index.showed | 80 |
| abstract_inverted_index.signal | 132 |
| abstract_inverted_index.(43.75% | 91 |
| abstract_inverted_index.(76.56% | 98 |
| abstract_inverted_index.(JAK2), | 131 |
| abstract_inverted_index.(STAT3) | 139 |
| abstract_inverted_index.(VEGFA) | 35, 146 |
| abstract_inverted_index.(n=64). | 52 |
| abstract_inverted_index.24.19%, | 93 |
| abstract_inverted_index.48.39%, | 100 |
| abstract_inverted_index.Results | 79 |
| abstract_inverted_index.control | 48, 54, 89 |
| abstract_inverted_index.disease | 88 |
| abstract_inverted_index.divided | 44 |
| abstract_inverted_index.groups: | 47 |
| abstract_inverted_index.months) | 117 |
| abstract_inverted_index.months, | 108 |
| abstract_inverted_index.ovarian | 13 |
| abstract_inverted_index.overall | 102, 159 |
| abstract_inverted_index.therapy | 10, 73, 149 |
| abstract_inverted_index.addition | 75 |
| abstract_inverted_index.adjuvant | 64 |
| abstract_inverted_index.advanced | 12 |
| abstract_inverted_index.compared | 118 |
| abstract_inverted_index.efficacy | 6 |
| abstract_inverted_index.evaluate | 4 |
| abstract_inverted_index.improved | 87 |
| abstract_inverted_index.pathway. | 36 |
| abstract_inverted_index.patients | 41 |
| abstract_inverted_index.received | 56, 69 |
| abstract_inverted_index.research | 67, 83 |
| abstract_inverted_index.response | 96 |
| abstract_inverted_index.standard | 77 |
| abstract_inverted_index.surgery, | 61 |
| abstract_inverted_index.survival | 103, 112, 157 |
| abstract_inverted_index.vascular | 141 |
| abstract_inverted_index.activator | 26, 135 |
| abstract_inverted_index.controls. | 120 |
| abstract_inverted_index.debulking | 60 |
| abstract_inverted_index.efficacy, | 153 |
| abstract_inverted_index.enrolled, | 43 |
| abstract_inverted_index.objective | 95 |
| abstract_inverted_index.survival. | 160 |
| abstract_inverted_index.P=0.0011), | 101 |
| abstract_inverted_index.P=0.0206), | 94 |
| abstract_inverted_index.prolonging | 155 |
| abstract_inverted_index.transducer | 24, 133 |
| abstract_inverted_index.treatment. | 78 |
| abstract_inverted_index.12.08±2.25 | 116 |
| abstract_inverted_index.22.92±7.26 | 107 |
| abstract_inverted_index.Bevacizumab | 121 |
| abstract_inverted_index.bevacizumab | 8, 71 |
| abstract_inverted_index.endothelial | 31, 142 |
| abstract_inverted_index.expression. | 147 |
| abstract_inverted_index.maintenance | 9, 72 |
| abstract_inverted_index.neoadjuvant | 57 |
| abstract_inverted_index.(16.08±2.46 | 113 |
| abstract_inverted_index.(30.45±7.69 | 104 |
| abstract_inverted_index.P<0.0001) | 109 |
| abstract_inverted_index.demonstrated | 150 |
| abstract_inverted_index.(JAK2)/signal | 23 |
| abstract_inverted_index.chemotherapy, | 58 |
| abstract_inverted_index.chemotherapy. | 65 |
| abstract_inverted_index.postoperative | 63, 70 |
| abstract_inverted_index.significantly | 86, 154 |
| abstract_inverted_index.transcription | 28, 137 |
| abstract_inverted_index.(STAT3)/vascular | 30 |
| abstract_inverted_index.progression-free | 111, 156 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8199999928474426 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.39626963 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |